VO-OHPic 是一种可逆的非竞争性 PTEN 抑制剂,对人源靶点的 IC50 值为 46 nM,可抑制 PTEN 信号通路,激活 Akt-GSK3β 和 Nrf-2/HO-1 通路,诱导凋亡 (apoptosis) 抵抗,提升 IL-10 水平,并抑制自噬 (autophage)、铁死亡 (ferroptosis) 和氧化应激,可用于急性心肌梗死、椎间盘退变、心肌病及癌症的研究。
产品编号: MS-J41137 CAS No.: 675848-25-6 分子式: C12H10N2O8V 分子量: 361.16
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
询价
10mg
询价
询价

产品描述

VO-OHPic 是一种可逆的非竞争性 PTEN 抑制剂,对人源靶点的 IC50 值为 46 nM,可抑制 PTEN 信号通路,激活 Akt-GSK3β 和 Nrf-2/HO-1 通路,诱导凋亡 (apoptosis) 抵抗,提升 IL-10 水平,并抑制自噬 (autophage)、铁死亡 (ferroptosis) 和氧化应激,可用于急性心肌梗死、椎间盘退变、心肌病及癌症的研究。

生物实验数据

生物活性 VO-OHPic is a reversible, non-competitive PTEN inhibitor with an IC50 of 46 nM against the human target that inhibits the PTEN signaling pathway, activates the Akt-GSK3β and Nrf-2/HO-1 pathways, induces apoptosis resistance, elevates IL-10 levels, and suppresses autophagy (autophage), ferroptosis, and oxidative stress, and can be used for research on acute myocardial infarction, intervertebral disc degeneration, cardiomyopathy, and cancer.
IC50 & Target

Akt

 

IL-10

 

体外研究
(In Vitro)

VO-OHpic (0.05-2.0 μg/mL;2 小时) 可呈剂量依赖性地提高经 H/R 处理的离体成年大鼠心肌细胞的活力。
VO-OHpic (1 µM;24-72 小时) 以时间依赖的方式抑制 TSC2-/- MEF 的增殖。
VO-OHpic (1 µM;24-72 小时) 可过度抑制 TSC2-/- MEFs 中的自噬。
VO-OHpic (1 µM;24-72 小时) 可调控 TSC2-/- 小鼠胚胎成纤维细胞中的 PTEN/PRAS40 通路。
VO-OHPic (1 μM;24 小时) 通过恢复原代小鼠 CEP 软骨细胞中 GPX4 和 SLC7A11 的表达,抑制 TBHP 诱导的铁死亡。
VO-OHPic (1 μM;24 小时) 可抑制 TBHP 诱导的原代小鼠 CEP 软骨细胞中 ROS 的产生。
VO-OHPic (30 μM) 通过抑制 PTEN 并激活 PI3K/Akt 通路,减轻 IL-1β 诱导的人髓核细胞退变,从而恢复 II 型胶原蛋白和聚集蛋白聚糖的水平。
VO-OHPic (30 μM) 通过介导细胞周期从 G1 期向 S 期进展,促进 IL-1β 诱导的退变人髓核细胞增殖。
VO-OHPic (30 μM) 通过降低 ROS 水平并上调抗氧化酶 SOD1、SOD2、CAT 和 GSH,减轻 H2O2 诱导的退变人髓核细胞中的氧化应激。
VO-OHPic (1 μM;48 小时) 可通过上调 Nrf2 及其下游抗氧化蛋白的表达、促进 Nrf2 核转位,激活 Methylprednisolone (MS-O73978) 处理的大鼠内皮祖细胞中的 Nrf2 信号通路。
VO-OHPic (1 μM;48 小时) 可恢复经 Methylprednisolone 处理的大鼠内皮祖细胞的正常线粒体形态。
VO-OHPic (1 μM;48 小时) 可抑制 Methylprednisolone 诱导的大鼠内皮祖细胞中活性氧的过度生成。
VO-OHPic (1 μM;48 小时) 需要激活 Nrf2 才能在 Methylprednisolone 处理的大鼠内皮祖细胞中发挥抗凋亡、抗氧化和促血管生成作用。
VO-OHpic (15-300 nM;10 分钟) 以非竞争性方式可逆抑制纯化的重组 PTEN,其 IC50 为 46 nM。

Cell Proliferation Assay

Cell Line: TSC2-/- murine embryonic fibroblasts (MEFs)
Concentration: 1 µM
Incubation Time: 24 h; 48 h; 72 h
Result: Reduced relative cell viability significantly at 48 h (P=0.005) and 72 h (P<0.001).
Showed no significant difference in relative cell viability at 24 h (P=0.333).

Western Blot Analysis

Cell Line: TSC2-/- murine embryonic fibroblasts (MEFs)
Concentration: 1 µM
Incubation Time: 24 h; 48 h; 72 h
Result: Reduced relative expression of LC3-I significantly at 24 h (P<0.001), 48 h (P=0.015), and 72 h (P=0.001).
Reduced relative expression of LC3-II significantly at 24 h (P=0.020), 48 h (P<0.001), and 72 h (P=0.007).\nReduced relative expression ratio of p-PTEN/PTEN significantly at 24 h (P=0.001), 48 h (P=0.005), and 72 h (P=0.011).
Reduced relative expression ratio of p-PRAS40/PRAS40 significantly at 48 h (P<0.001) and 72 h (P<0.001).
Showed no significant difference in relative expression ratio of p-PRAS40/PRAS40 at 24 h (P=0.137).

Cell Viability Assay

Cell Line: human nucleus pulposus (NP) cells
Concentration: 10 μM; 30 μM; 50 μM; 100 μM
Incubation Time: 48 h
Result: Achieves the highest cell viability at 30 μM compared to all other tested concentrations.

Western Blot Analysis

Cell Line: rat endothelial progenitor cells (EPCs)
Concentration: 1 μM
Incubation Time: 48 h
Result: Reversed MPS-induced increases in cleaved caspase-3, cleaved caspase-9, cytochrome C, and Bax protein expression.
Restored MPS-reduced Bcl-xL expression and the p-Bad/Bad ratio.
Suppressed MPS-promoted formation of the Bad/Bcl-xL pro-apoptotic complex.
Attenuated MPS-induced Bax translocation to mitochondria and cytochrome C release from mitochondria to cytoplasm.\nReversed MPS-induced reductions in SIRT1, Nrf2, HO-1, NQO-1, and Trx protein expression.
Increased nuclear Nrf2 localization, which was suppressed by MPS.

ELISA Assay

Cell Line: rat endothelial progenitor cells (EPCs)
Concentration: 1 μM
Incubation Time: 48 h
Result: Significantly increased VEGF concentration in the culture medium relative to the MPS-only group, reversing MPS-suppressed EPC VEGF secretion.
体内研究
(In Vivo)

VO-OHpic (10 mg/kg;腹腔注射;隔日一次;持续 12 周) 可减轻手术诱导椎间盘退变 (IDD) 小鼠的 IDD 进展及软骨终板钙化。
VO-OHpic (10 mg/kg;腹腔注射;每 2 天 1 次) 可减轻大鼠 LPS (MS-X54539) 和 Methylprednisolone 诱导的股骨头坏死,提升骨体积相关参数,减少骨空陷窝数量,并促进股骨头血管生成。

Animal Model: C57BL/6 (8-week-old male; surgically induced intervertebral disc instability)
Dosage: 10 mg/kg
Administration: i.p.; every other day; 12 weeks
Result: Reduced intervertebral disc degeneration histological score significantly compared to the IDD-only group.
Improved intervertebral disc height significantly compared to the IDD-only group.
Reduced bone volume/tissue volume (BV/TV) of the cartilage endplate significantly compared to the IDD-only group.
Increased COL2-positive cell levels in the cartilage endplate compared to the IDD-only group.
Decreased MMP3-positive cell levels in the cartilage endplate compared to the IDD-only group.
Increased Nrf-2-positive cell levels in the cartilage endplate compared to the IDD-only group.
Reduced COL10 and OCN-positive cell levels in the cartilage endplate compared to the IDD-only group.
Animal Model: Sprague-Dawley (male, 7 weeks old, body weight 250-300 g, osteonecrosis of the femoral head model induced by LPS + Methylprednisolone)
Dosage: 10 mg/kg
Administration: i.p.; every 2 days
Result: Significantly increased bone volume and bone volume/total volume compared to the methylprednisolone-only group.
Decreased bone surface/trabecular bone volume compared to the methylprednisolone-only group.
Reduced the number of empty bone lacunae in the femoral head compared to the methylprednisolone-only group.
Increased the relative staining intensity of CD31, VEGF, and VEGFR2 in subchondral bone trabeculae compared to the methylprednisolone-only group.
Increased the number of CD31-positive and VEGFR2-positive blood vessels per field compared to the methylprednisolone-only group.

化学信息

分子量 361.16
分子式 C12H10N2O8V
CAS No. 675848-25-6

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础